Generic Medicine Info
Indications and Dosage
Allergic conditions
Adult: 25 mg 6-8 hrly. Max: 75 mg 24 hrly.
Child: 6-11 yr 12.5 mg 6-8 hrly. Max: 37.5 mg 24 hrly; ≥12 yr Same as adult dose.

Motion sickness
Child: ≥6 yr As chewable tab: 25 mg 6-8 hrly taken up to 1 hr before travel or at onset of symptoms.
Emphysema, chronic bronchitis, glaucoma, enlarged prostate gland.
Special Precautions
Childn. Pregnancy and lactation.
Adverse Reactions
Significant: Drowsiness, excitability.
Patient Counseling Information
This drug may cause drowsiness, if affected, do not drive or operate machinery.
Drug Interactions
May enhance the action of epinephrine.
Description: Chlorcyclizine, a piperazine derivative, is a sedating antihistamine given for the symptomatic relief of hypersensitivity reactions. Additionally, it has some local anaesthetic, anticholinergic, antiserotonergic properties, and can be used as an antiemetic.
Absorption: Readily absorbed. Time to peak plasma concentration: 5 hr.
Distribution: Widely distributed throughout the body. Plasma protein binding: 85-90%.
Metabolism: Metabolised via N-demethylation to norchlorcyclizine and via N-oxidation to chlorcyclizine N-oxide.
Excretion: Via urine (as norchlorcyclizine and approx 0.5% as chlorcyclizine N-oxide).
Chemical Structure

Chemical Structure Image

Source: National Center for Biotechnology Information. PubChem Database. Chlorcyclizine, CID=2710, (accessed on Jan. 21, 2020)

Store between 20-25°C.
MIMS Class
Antiemetics / Antihistamines & Antiallergics
ATC Classification
R06AE04 - chlorcyclizine ; Belongs to the class of piperazine derivatives used as systemic antihistamines.
Ahist Tablet (Magna Pharmaceuticals, Inc.). DailyMed. Source: U.S. National Library of Medicine. Accessed 21/02/2017.

Bonine Kids Tablet, Chewable (Insight Pharmaceuticals). DailyMed. Source: U.S. National Library of Medicine. Accessed 21/02/2017.

Buckingham R (ed). Chlorcyclizine Hydrochloride. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. Accessed 21/02/2017.

Chlorcyclizine. National Center for Biotechnology Information. PubChem Database. Accessed 21/02/2017.

Disclaimer: This information is independently developed by MIMS based on Chlorcyclizine from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2022 MIMS. All rights reserved. Powered by
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in